TELEPRO: Patient‐Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World

BACKGROUND. When carcinoid syndrome (CS) diarrhea (CSD) is inadequately controlled with long‐acting somatostatin analogs (SSAs), clinical practice guidelines recommend addition of the tryptophan hydroxylase inhibitor telotristat ethyl (TE). In a 12‐week multinational, randomized controlled trial, TE...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Strosberg, Jonathan, Joish, Vijay N., Giacalone, Susan, Perez‐Olle, Raul, Fish‐Steagall, Ann, Kapoor, Kanika, Dharba, Sam, Lapuerta, Pablo, Benson, Al B.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Endocrinology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853091/
https://ncbi.nlm.nih.gov/pubmed/31189618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0921
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars